Professional
Added to YB: 2024-02-26
Pitch date: 2024-02-25
LLY [bullish]
Eli Lilly and Company
+34.85%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$761.96
Price Target
N/A
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
growth
Aristotle Capital Core Equity New Position - Eli Lilly and Company
$LLY: US pharma giant w/ focus on diabetes, oncology, immunology & neuroscience. Blockbusters Trulicity, Verzenio, Taltz drive revenue. Strong pipeline: Orforglipron oral GLP-1, retatrutide triple incretin agonist build on Mounjaro's success, expanding to heart disease, apnea, liver & kidney disorders. Premium valuation on robust growth outlook.
Read full article (1 min)